formationbio

Vice President, Trial Engine

Apply Now

At a Glance

Location
New York, NY; Boston, MA
Compensation
alary range for this role is: $333,000 - $370,000 Salary ranges are informed by
Posted
2026-03-11T17:17:10-04:00

Key Requirements

Domain Knowledge

  • Automation
  • Clinical

Benefits & Perks

Health Insurance

y, we offer equity, comprehensive benefits, generous perks, hybrid flexibility, an

Requirements

Outcome-Driven: You optimize for value creation, everything is in service of that.

AI-Native: You naturally embed AI and automation into team culture, workflows, and decision-making and believe this is the future of exceptional clinical trial execution.

Generalist with Range: You flex across disciplines, know when to go deep, when to pull in experts, and when to rely on strong teams.

Formation Bio is prioritizing hiring in key hubs, primarily the New York City and Boston metro areas. These positions will follow a hybrid work model with 1-3 days required at the office.  Applicants from the Research Triangle (NC) and San Francisco Bay Area may also be considered.

Please only apply if you reside in these locations or are willing to relocate.

Compensation & Benefits

Salary ranges are informed by a number of factors including geographic location. The range provided includes base salary only. In addition to base salary, we offer equity, comprehensive benefits, generous perks, hybrid flexibility, and more. If this range doesn't match your expectations, please still apply because we may have something else for you.

You will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.

Responsibilities

As Vice President of Trial Engine, you are the accountable leader for how Formation Bio executes clinical trials across our portfolio. This role builds on an existing, differentiated trial execution and data platform, and is accountable for scaling and strengthening it as the portfolio grows. That means running and continuously improving a trial execution engine that delivers speed, cost efficiency, and quality predictably. You will optimize planning and execution across our trials and drive iteration and improvement across every part of our delivery approach.

We’re not looking for a traditional Clinical Operations leader. This is an outcomes oriented, first principled, velocity-obsessed, player + coach + builder role for someone who knows clinical trials can and must be run faster, cheaper, and better at the same time. You will lead multiple functions, serve as a trial team leader yourself, and work in close partnership with the Development, Translational, Technology, Business Operations & Strategy and Quality teams to continue to build capabilities, including AI enabled, that ensure we deliver new treatments to patients faster and more efficiently. If you want a steady-state org, inherited process, and the ability to rely solely on your experience, you’re not the right person.

Own and Drive Trial Outcomes

Own end-to-end trial execution across the portfolio, with direct accountability for delivery against asset and portfolio value inflection goals

Serve as trial team leader on designated programs, setting execution pace and ensuring learnings are shared and implemented across the portfolio

About the Company

Formation Bio is a tech and AI driven pharma company differentiated by radically more efficient drug development.

Advancements in AI and drug discovery are creating more candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately limit the number of new medicines that can reach patients, Formation Bio, founded in 2016 as TrialSpark Inc., has built technology platforms, processes, and capabilities to accelerate all aspects of drug development and clinical trials. Formation Bio partners, acquires, or in-licenses drugs from pharma companies, research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to bring new medicines to patients. The company is backed by investors across pharma and tech, including a16z, Sequoia, Sanofi, Thrive Capital, Sam Altman, John Doerr, Spark Capital, SV Angel Growth, and others.

You can read more at the following links:

Our Vision for AI in Pharma

Our Current Drug Portfolio

Our Technology & Platform